To Top


Overview and Mechanism of Action

CM24 is a clinical stage humanized monoclonal antibody directed against CEACAM1, a multi-faceted membrane protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family that acts as an immune checkpoint inhibitor, a pro-angiogenic, anti-apoptotic agent and a promoter of tumor invasiveness and metastases. Evidence has shown that CEACAM1 is expressed on different white blood cells including lymphocytes neutrophils and monocytes and its expression is up-regulated in several cancer types. Additionally, previous publications in the scientific literature indicate that CEACAM1 is expressed on neutrophil extracellular traps (NETs) which, among other activities, are believed to promote metastatic processes of tumors. Preclinical studies have shown evidence that CM24 enhances the cytotoxic activity of tumor-infiltrating lymphocytes (TILs) against various CEACAM1-positive tumor cell lines in vitro and in vivo. We have recently shown that CM24 attenuates NET-induced tumor cell migration. CM24 is being developed for multiple oncological indications according to the expression pattern of its target protein.

Neutrophil extracellullar trap-associated CEACAM1 as a putative therapeutic target to prevent metastatic progression:

CEACAM1 creates a pro-angiogenic tumor microenviroment that supports tumor vessels maturation. CM24 is proposed to attenuate/block tumor growth anbd metastatic processes.

Clinical Studies

In a Phase 1 dose-escalation study, CM24 demonstrated a good safety profile and promising efficacy signals. We are developing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors and standard of care chemotherapy in a Phase 2 study in patients with pancreatic ductal adenocarcinoma (PDAC). We entered into a clinical collaboration agreement with Bristol Myers Squibb for this study.

CM24 - References (Download) NCT04731467 - A Phase 1/2 Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Skip to content